VR Logo

Unrated

Nippon India Pharma Fund - Direct Plan


Equity: Sectoral-Pharma

1 Lakh

Investment Grown to
₹ 1.72 Lakh

₹ 10000

Monthly SIP Grown to
₹ 5.26 Lakh

Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund 41.74 -0.59 1.52 13.75 20.67 33.16 56.17 19.84 8.95 18.59 --
S&P BSE Healthcare TRI 40.53 -0.32 2.64 15.44 24.81 32.13 50.60 11.33 2.03 12.04 --
Equity: Sectoral-Pharma 43.46 -0.13 2.76 15.22 22.56 33.72 56.80 15.21 6.15 16.28 --
Rank within category 6 9 8 9 6 6 6 1 1 1 --
Number of funds in category 9 9 9 9 9 9 9 4 3 3 0

As on 07-Aug-2020

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 56.17 19.84 8.95 1.35 3,093
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 58.97 -- -- 1.37 1,523
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 56.77 11.19 4.15 1.23 1,154
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 65.14 -- -- 0.83 640
DSP Healthcare Fund - Direct Plan  | Invest Online
Unrated
Nov-18 69.19 -- -- 1.04 571

Best & Worst Performance

Best (Period) Worst (Period)
Week 21.40 (01-Apr-2020 - 09-Apr-2020) -12.21 (05-Mar-2020 - 12-Mar-2020)
Month 38.63 (23-Mar-2020 - 22-Apr-2020) -21.01 (20-Feb-2020 - 23-Mar-2020)
Quarter 47.66 (23-Mar-2020 - 22-Jun-2020) -14.04 (29-Dec-2015 - 29-Mar-2016)
Year 67.54 (30-Sep-2013 - 30-Sep-2014) -15.12 (08-Sep-2016 - 08-Sep-2017)

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund 19.26 20.89 0.67 1.51 0.85 8.44
S&P BSE Healthcare TRI 11.82 23.98 0.28 0.67 -- --
Equity: Sectoral-Pharma 15.06 21.16 0.47 0.97 0.86 4.19
Rank within category 1 2 1 1 2 1
Number of funds in category 4 4 4 4 4 4

The Risk Measures have been calculated using calendar month returns for the last three years.

As on 31-Jul-2020

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 19
Top 10 Stocks (%) 77.42
Top 5 Stocks (%) 48.99
Top 3 Sectors (%) 98.07
Portfolio P/B Ratio 3.57
Portfolio P/E Ratio 32.88

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 31,119 28,993
Giant (%) 9.83 10.94
Large (%) 56.07 46.71
Mid (%) 22.95 27.43
Small (%) 11.15 14.92
Tiny (%) -- --

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
down Aurobindo Pharma Healthcare 18.77 11.96 5.49 10.48
equal Cipla Healthcare 35.69 11.10 5.81 9.94
equal Sun Pharmaceutical Inds. Healthcare 174.77 12.32 7.94 9.64
equal Dr. Reddy's Lab Healthcare 39.09 11.04 5.71 9.50
up Lupin Healthcare -- 9.43 3.33 9.43
down Divi's Laboratories Healthcare 46.31 11.76 7.74 7.74
up Syngene International Healthcare 47.41 7.15 0.00 6.35
up Fortis Healthcare (India) Healthcare 179.76 6.89 0.00 5.68
equal Sanofi India Healthcare 42.33 10.26 4.46 4.46
up Thyrocare Technologies Healthcare 60.45 7.24 3.63 4.20
equal Cadila Healthcare Healthcare 30.14 4.02 0.00 3.99
down Biocon Healthcare 69.32 9.36 0.00 3.91
equal Abbott India Healthcare 52.41 11.05 3.57 3.57
up Narayana Hrudayalaya Healthcare -- 3.72 1.04 2.83
equal Alkem Laboratories Healthcare 26.13 6.36 0.11 2.38
equal Indoco Remedies Healthcare 93.20 2.50 0.00 2.14
up Laurus Labs Healthcare 26.62 1.34 0.00 1.34
equal Healthcare Global Enterprises Healthcare -- 3.72 0.26 0.42
new Glaxosmithkline Pharma Healthcare 278.02 0.07 0.00 0.07

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 30-Jun-2020

Fund Manager

— Sailesh Raj Bhan since 01-Jan-2013

Education: Mr. Bhan is an MBA (Finance) and CFA.

Experience: Mr. Sailesh Raj Bhan has about 19 years experience in equity research and fund management, with over 10 years at Reliance Nippon Life Asset Management Limited (formerly Reliance Capital Asset Management Limited). He manages diversified equity schemes like Reliance Equity Opportunities Fund (the largest Flexicap Scheme in India with assets of USD 800 million) since its inception in 2005 and Reliance Top200 Fund (a large cap diversified equity fund) since its inception in 2007. In addition, for over 9 years, he has been managing two specialized sector funds - Reliance Pharma Sector Fund (the largest pharma sector fund in India) and Reliance Media and Entertainment Fund.

Funds Managed:


-0.59%

Change from previous, NAV as on 07-Aug-2020

Growth: ₹ 228.2881

Dividend: ₹ 85.8133

Bonus: ₹ 228.2881


Investment Strategy

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.

Investment Details

Minimum Investment (₹) 5,000
Minimum Addl Investment (₹) 1,000
Minimum SIP Investment (₹) 500
Minimum No of Cheques 60
Minimum Withdrawal (₹) 100
Minimum Balance (₹) 1
Exit Load 1% for redemption within 30 days

Basic Details

Fund House: Nippon India Mutual Fund
Launch Date: 01-Jan-2013
Return Since Launch: 16.86%
Benchmark: S&P BSE Healthcare TRI
Riskometer: High
Type: Open-ended
Assets: ₹ 3,093 Cr (As on 30-Jun-2020)
Expense: 1.35% (As on 30-Jun-2020)
Risk Grade: --
Return Grade: --
Turnover: 34.00%

Most Recent Dividends

Plan Record Date Dividend (₹ / Unit)  
Dividend28-Feb-20203.9843

 05-Mar-20194.4270
 05-Mar-20186.0000
 06-Mar-20176.5000
 04-Mar-20167.0000
 30-Jan-20157.0000
 14-Feb-20144.5000

Contact Information

AMC: Nippon India Life Asset Management Ltd.

Address: Reliance Centre, 7th Floor, South Wing Off Western Express Highway Santacruz (East) Mumbai - 400055

Phone: 022-68334800 / 18602660111

Fax: 022-33037662

Email: [email protected]

Website: http://www.nipponindiamf.com

Registrar & Transfer Agent: KFin Technologies Pvt Ltd.

Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016

Phone: 040-44857874

Email: [email protected]

Website: www.karvymfs.com

Upcoming Video

Investors' Hangout

Attaining financial independence

dateFriday, 14-Aug-2020
time12:30 PM - 01:00 PM